Carnegie acted as joint bookrunner in Faron Pharmaceuticals’ directed share issue of 6,976,744 shares at a subscription price of EUR 1.72 per share.
Faron Pharmaceuticals is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration.